2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Cencora company profile · pharmaceutical distribution, specialty & services · history · financial snapshot · S&P 500 rank #197 · Cencora 業務歷史財務與標普500地位
SNAPSHOT
| Ticker | COR (NYSE) |
| Company | Cencora, Inc. |
| GICS sector / industry | Health Care (XLV) / Health Care Distributors |
| S&P 500 rank (by weight) | #197 · 0.09% (Oct 31, 2026) |
| Sector rank (by index weight) | #24 in Health Care (Oct 31, 2026) |
| Headquarters | Conshohocken, Pennsylvania |
| Founded | August 28, 2001, by the merger of AmeriSource Health and Bergen Brunswig (renamed Cencora in 2023) |
| CEO | Robert P. Mauch (President & CEO) |
| Employees | More than 51,000 globally, ≈47,000 full-time (Sep 30, 2025, FY2025 10-K) |
| Market cap | $63.13B (Oct 31, 2026) |
| SEC filings | EDGAR — CIK 0001140859 |
WHAT IT DOES
Cencora, formerly AmerisourceBergen, is a pharmaceutical solutions organization that sources and distributes branded, generic and specialty pharmaceuticals and provides services to healthcare providers, pharmacies and pharmaceutical and biotech manufacturers. It serves customers through a geographically diverse network of distribution service centers and other operations in the United States and select global markets.
FY2025 revenue was $321,332.8 million, up 9.3% from $293,958.6 million in FY2024. U.S. Healthcare Solutions supplied $290,982.0 million of that revenue, including human health distribution of $285,287.5 million and animal health of $5,694.5 million; International Healthcare Solutions supplied $30,366.3 million. Total segment operating income rose 15.8% to $4,223.0 million, while consolidated operating income was $2,628.6 million after goodwill impairment, acquisition-related and litigation items.
Growth in FY2025 was led by U.S. human health distribution (+9.7%), helped by specialty pharmaceuticals and by the January 2025 acquisition of Retina Consultants of America (RCA), and by drug utilization trends including GLP-1 products for diabetes and weight loss, as described in the 10-K. The business model is high-volume and thin-margin: consolidated operating income was 0.8% of revenue in FY2025.
BUSINESS SEGMENTS — FY2025 REVENUE
| Segment | Revenue | Share | YoY |
|---|---|---|---|
| U.S. Healthcare Solutions | $290.98B | 90.6% | +9.7% |
| International Healthcare Solutions | $30.37B | 9.4% | +6.1% |
| Total revenue | $321.33B | 100% | +9.3% |
HISTORY
| Year | Milestone |
|---|---|
| 2001 | Formed on August 28, 2001, by the merger of AmeriSource Health Corporation and Bergen Brunswig Corporation, as AmerisourceBergen Corporation |
| 2023 | Expands contract research and consulting with the PharmaLex acquisition |
| 2023 | Changes its name to Cencora, Inc. on August 30, 2023, and begins trading under the new name |
| 2025 | Acquires an 85% interest in Retina Consultants of America (RCA) on January 2, 2025, for $4,042.0 million in cash plus contingent consideration |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2025
| Revenue | $321.33B (+9.3% YoY, vs $293.96B in FY2024) |
| Operating income | $2.63B (+20.8% YoY, vs $2.18B in FY2024) |
| Total segment operating income | $4.22B (+15.8% YoY) |
| Net income attributable to Cencora | $1.55B (vs $1.51B in FY2024) |
| Diluted EPS | $7.96 (vs $7.53 in FY2024) |
| Goodwill impairment (FY2025) | $723.9M, including PharmaLex goodwill |
| Employees | More than 51,000 globally (Sep 30, 2025) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Cencora is the S&P 500’s pharmaceutical-distribution lever: at a 0.09% index weight and #24 in Health Care by index weight, its revenue tracks U.S. drug utilization — specialty launches, GLP-1 volumes and generic conversion — more directly than any drug manufacturer in the index.
Because it touches nearly every prescription channel, its results also read as a gauge of healthcare spending itself: when utilization rises, Cencora’s volumes rise first, even though its margin per dollar stays thin.
SOURCES & METHODOLOGY
| Market data | Slickcharts S&P 500 by weight (rank, weight, price — Oct 31, 2026 crawl) · StockAnalysis (market cap — Oct 31, 2026 crawl) |
| Financials | Cencora FY2025 Form 10-K (SEC EDGAR, filed Nov 25, 2025; fiscal year ended Sep 30, 2025) |
| Sector classification | GICS via the List of S&P 500 companies (Wikipedia) |
| Library data | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 代碼 | COR(NYSE) |
| 公司 | Cencora, Inc. |
| GICS 板塊/行業 | 醫療保健(XLV)/醫療保健分銷商 |
| 標普500排名(按權重) | #197 · 0.09%(2026 年 10 月 31 日) |
| 板塊內排名(按指數權重) | 醫療保健第 #24(2026 年 10 月 31 日) |
| 總部 | 美國賓夕法尼亞州康舍霍肯 |
| 成立 | 2001 年 8 月 28 日,由 AmeriSource Health 與 Bergen Brunswig 合併成立(2023 年更名為 Cencora) |
| 行政總裁 | Robert P. Mauch(總裁兼行政總裁) |
| 員工 | 全球逾 51,000,約 47,000 全職(2025 年 9 月 30 日,FY2025 10-K) |
| 市值 | $63.13B(2026 年 10 月 31 日) |
| SEC 申報 | EDGAR — CIK 0001140859 |
業務概覽
Cencora(前稱 AmerisourceBergen)是一家醫藥解決方案機構,採購並分銷品牌藥、仿製藥與專科藥,並為醫療服務提供者、藥房及製藥與生物科技製造商提供服務。公司透過遍佈美國與部分全球市場的分銷服務中心網絡服務客戶。
FY2025 收入為 $3,213.328 億,同比增長 9.3%(FY2024 為 $2,939.586 億)。美國醫療保健解決方案貢獻 $2,909.820 億,包括人體健康分銷 $2,852.875 億與動物健康 $56.945 億;國際醫療保健解決方案貢獻 $303.663 億。板塊營業利潤合計增長 15.8% 至 $42.230 億;合併營業利潤在商譽減值、收購相關與訴訟項目後為 $26.286 億。
FY2025 增長由美國人體健康分銷帶動(+9.7%),受惠於專科藥與 2025 年 1 月收購的 Retina Consultants of America(RCA),以及 10-K 所述藥物使用趨勢(包括糖尿病與減重用 GLP-1 產品)。業務模式是高週轉、薄利潤:FY2025 合併營業利潤僅佔收入 0.8%。
業務板塊 — FY2025 收入
| 板塊 | 收入 | 佔比 | 同比 |
|---|---|---|---|
| 美國醫療保健解決方案 | $290.98B | 90.6% | +9.7% |
| 國際醫療保健解決方案 | $30.37B | 9.4% | +6.1% |
| 總收入 | $321.33B | 100% | +9.3% |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 2001 | 於 2001 年 8 月 28 日由 AmeriSource Health Corporation 與 Bergen Brunswig Corporation 合併成立,名為 AmerisourceBergen Corporation |
| 2023 | 透過收購 PharmaLex 擴展合約研究與顧問業務 |
| 2023 | 於 2023 年 8 月 30 日更名為 Cencora, Inc.,並以新名稱交易 |
| 2025 | 於 2025 年 1 月 2 日以 $40.420 億現金加或有對價收購 Retina Consultants of America(RCA)85% 權益 |
競爭地位
財務快照 — FY2025
| 收入 | $321.33B(同比 +9.3%,FY2024 為 $293.96B) |
| 營業利潤 | $2.63B(同比 +20.8%,FY2024 為 $2.18B) |
| 板塊營業利潤合計 | $4.22B(同比 +15.8%) |
| 歸屬 Cencora 淨利潤 | $1.55B(FY2024 為 $1.51B) |
| 攤薄每股盈利 | $7.96(FY2024 為 $7.53) |
| 商譽減值(FY2025) | $723.9M,包括 PharmaLex 商譽 |
| 員工 | 全球逾 51,000(2025 年 9 月 30 日) |
主要風險
對標普500的重要性
Cencora 是標普500中醫藥分銷的槓桿:指數權重 0.09%、醫療保健板塊指數權重第 #24,其收入比指數中任何製藥商都更直接地追蹤美國藥物使用量——專科新藥上市、GLP-1 銷量與仿製藥轉換。
由於它觸及幾乎所有處方渠道,其業績亦是醫療開支本身的讀數:使用量上升時,Cencora 的銷量最先上升,即使每美元毛利維持微薄。
來源與方法
| 市場數據 | Slickcharts 標普500權重榜(排名、權重、價格——2026 年 10 月 31 日抓取)· StockAnalysis(市值——2026 年 10 月 31 日抓取) |
| 財務 | Cencora FY2025 Form 10-K(SEC EDGAR,2025 年 11 月 25 日申報;財政年度截至 2025 年 9 月 30 日) |
| 板塊分類 | GICS,據 S&P 500 公司清單(Wikipedia) |
| 圖庫數據 | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-10-31 11:33 · updated 2026-11-14 23:12 · rev 6